Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

Increased copy number alterations, indicative of chromosomal instability, is associated with poor cancer outcome. Here, metastatic colorectal cancer patients displaying intermediate-high CIN associate with improved outcome following chemotherapy and bevacizumab treatment, suggesting CIN as a predict...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dominiek Smeets, Ian S. Miller, Darran P. O’Connor, Sudipto Das, Bruce Moran, Bram Boeckx, Timo Gaiser, Johannes Betge, Ana Barat, Rut Klinger, Nicole C. T. van Grieken, Chiara Cremolini, Hans Prenen, Massimiliano Mazzone, Jeroen Depreeuw, Orna Bacon, Bozena Fender, Joseph Brady, Bryan T. Hennessy, Deborah A. McNamara, Elaine Kay, Henk M. Verheul, Neerincx Maarten, William M. Gallagher, Verena Murphy, Jochen H. M. Prehn, Miriam Koopman, Cornelis J. A. Punt, Fotios Loupakis, Matthias P. A. Ebert, Bauke Ylstra, Diether Lambrechts, Annette T. Byrne
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d17fc441244b44c587907023fe2c93dd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d17fc441244b44c587907023fe2c93dd
record_format dspace
spelling oai:doaj.org-article:d17fc441244b44c587907023fe2c93dd2021-12-02T15:34:41ZCopy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy10.1038/s41467-018-06567-62041-1723https://doaj.org/article/d17fc441244b44c587907023fe2c93dd2018-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06567-6https://doaj.org/toc/2041-1723Increased copy number alterations, indicative of chromosomal instability, is associated with poor cancer outcome. Here, metastatic colorectal cancer patients displaying intermediate-high CIN associate with improved outcome following chemotherapy and bevacizumab treatment, suggesting CIN as a predictive biomarker.Dominiek SmeetsIan S. MillerDarran P. O’ConnorSudipto DasBruce MoranBram BoeckxTimo GaiserJohannes BetgeAna BaratRut KlingerNicole C. T. van GriekenChiara CremoliniHans PrenenMassimiliano MazzoneJeroen DepreeuwOrna BaconBozena FenderJoseph BradyBryan T. HennessyDeborah A. McNamaraElaine KayHenk M. VerheulNeerincx MaartenWilliam M. GallagherVerena MurphyJochen H. M. PrehnMiriam KoopmanCornelis J. A. PuntFotios LoupakisMatthias P. A. EbertBauke YlstraDiether LambrechtsAnnette T. ByrneNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Dominiek Smeets
Ian S. Miller
Darran P. O’Connor
Sudipto Das
Bruce Moran
Bram Boeckx
Timo Gaiser
Johannes Betge
Ana Barat
Rut Klinger
Nicole C. T. van Grieken
Chiara Cremolini
Hans Prenen
Massimiliano Mazzone
Jeroen Depreeuw
Orna Bacon
Bozena Fender
Joseph Brady
Bryan T. Hennessy
Deborah A. McNamara
Elaine Kay
Henk M. Verheul
Neerincx Maarten
William M. Gallagher
Verena Murphy
Jochen H. M. Prehn
Miriam Koopman
Cornelis J. A. Punt
Fotios Loupakis
Matthias P. A. Ebert
Bauke Ylstra
Diether Lambrechts
Annette T. Byrne
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
description Increased copy number alterations, indicative of chromosomal instability, is associated with poor cancer outcome. Here, metastatic colorectal cancer patients displaying intermediate-high CIN associate with improved outcome following chemotherapy and bevacizumab treatment, suggesting CIN as a predictive biomarker.
format article
author Dominiek Smeets
Ian S. Miller
Darran P. O’Connor
Sudipto Das
Bruce Moran
Bram Boeckx
Timo Gaiser
Johannes Betge
Ana Barat
Rut Klinger
Nicole C. T. van Grieken
Chiara Cremolini
Hans Prenen
Massimiliano Mazzone
Jeroen Depreeuw
Orna Bacon
Bozena Fender
Joseph Brady
Bryan T. Hennessy
Deborah A. McNamara
Elaine Kay
Henk M. Verheul
Neerincx Maarten
William M. Gallagher
Verena Murphy
Jochen H. M. Prehn
Miriam Koopman
Cornelis J. A. Punt
Fotios Loupakis
Matthias P. A. Ebert
Bauke Ylstra
Diether Lambrechts
Annette T. Byrne
author_facet Dominiek Smeets
Ian S. Miller
Darran P. O’Connor
Sudipto Das
Bruce Moran
Bram Boeckx
Timo Gaiser
Johannes Betge
Ana Barat
Rut Klinger
Nicole C. T. van Grieken
Chiara Cremolini
Hans Prenen
Massimiliano Mazzone
Jeroen Depreeuw
Orna Bacon
Bozena Fender
Joseph Brady
Bryan T. Hennessy
Deborah A. McNamara
Elaine Kay
Henk M. Verheul
Neerincx Maarten
William M. Gallagher
Verena Murphy
Jochen H. M. Prehn
Miriam Koopman
Cornelis J. A. Punt
Fotios Loupakis
Matthias P. A. Ebert
Bauke Ylstra
Diether Lambrechts
Annette T. Byrne
author_sort Dominiek Smeets
title Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
title_short Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
title_full Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
title_fullStr Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
title_full_unstemmed Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
title_sort copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/d17fc441244b44c587907023fe2c93dd
work_keys_str_mv AT dominieksmeets copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT iansmiller copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT darranpoconnor copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT sudiptodas copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT brucemoran copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT bramboeckx copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT timogaiser copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT johannesbetge copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT anabarat copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT rutklinger copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT nicolectvangrieken copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT chiaracremolini copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT hansprenen copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT massimilianomazzone copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT jeroendepreeuw copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT ornabacon copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT bozenafender copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT josephbrady copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT bryanthennessy copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT deborahamcnamara copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT elainekay copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT henkmverheul copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT neerincxmaarten copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT williammgallagher copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT verenamurphy copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT jochenhmprehn copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT miriamkoopman copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT cornelisjapunt copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT fotiosloupakis copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT matthiaspaebert copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT baukeylstra copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT dietherlambrechts copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
AT annettetbyrne copynumberloadpredictsoutcomeofmetastaticcolorectalcancerpatientsreceivingbevacizumabcombinationtherapy
_version_ 1718386808558977024

Ejemplares similares